menu
    • menu
    [{"orgOrder":0,"company":"Brii Biosciences","sponsor":"VBI Vaccines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ VBI Vaccines","highestDevelopmentStatusID":"7","companyTruncated":"Brii Biosciences \/ VBI Vaccines"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Not Applicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Brii Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0.44,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.44,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Brii Biosciences"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Brii Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Brii Biosciences"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Brii Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"VBI Vaccines \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Brii Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals for BRII-179

    Menu

    BRII-179

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VBI Vaccines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            VBI Vaccines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRII-179,Elebsiran

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Brii Biosciences

                            Deal Size : $33.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Brii Biosciences Announces Agreement To Acquire VBI's IP Rights In BRII-179

                            Details : Through the acquisition, Brii will get access to focus on the development of VBI-2601 (BRII-179), a protein-based HBV immunotherapeutic candidate intended for the treatment of chronic HBV infection.

                            Brand Name : VBI-2601

                            Molecule Type : Vaccine

                            Upfront Cash : $10.0 million

                            February 13, 2024

                            Lead Product(s) : BRII-179,Elebsiran

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Brii Biosciences

                            Deal Size : $33.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            VBI Vaccines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            VBI Vaccines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRII-179,VIR-2218

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Brii Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (...

                            Details : VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.

                            Brand Name : VBI-2601

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 06, 2023

                            Lead Product(s) : BRII-179,VIR-2218

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Brii Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            VBI Vaccines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            VBI Vaccines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRII-179

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Brii Biosciences

                            Deal Size : $437.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership to Address Both Prevention and Treatment in L...

                            Details : Under the collaboration, Brii Bio expanded its exclusive license to VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, to global rights and acquired an exclusive license for PreHevbri, VBI’s 3-antigen hepatitis B vaccine, in the Asia Pacific...

                            Brand Name : VBI-2601

                            Molecule Type : Vaccine

                            Upfront Cash : $15.0 million

                            July 05, 2023

                            Lead Product(s) : BRII-179

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Brii Biosciences

                            Deal Size : $437.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            VBI Vaccines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            VBI Vaccines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRII-179,VIR-2218

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and ...

                            Details : VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.

                            Brand Name : VBI-2601

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 15, 2023

                            Lead Product(s) : BRII-179,VIR-2218

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Brii Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Brii Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIR-2218,BRII-179

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022

                            Details : The data demonstrate that BRII-835 (VIR-2218), an small interfering ribonucleic acid that mediates RNA interference, results in dose-dependent reduction in hepatitis B surface antigen in Chinese patients with chronic HBV infection who received two doses ...

                            Brand Name : VIR-2218

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 31, 2022

                            Lead Product(s) : VIR-2218,BRII-179

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Brii Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Brii Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRII-179

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Brii Biosciences and VBI Vaccines Present Data from the Complete Phase 1b / 2a Study of BRII-179 in Patients w...

                            Details : The data demonstrate that BRII-179 (VBI-2601) provokes responses in both B cells (antibodies) and T cells of patients with chronic hepatitis B infection (HBV), and was well tolerated, with no signal detection safety.

                            Brand Name : VBI-2601

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 23, 2021

                            Lead Product(s) : BRII-179

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Brii Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Brii Biosciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRII-179

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : VBI Vaccines

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis...

                            Details : BRII-179 (VBI-2601) is a novel recombinant, protein-based immunotherapeutic candidate, which is being developed and led by Brii Bio in partnership with VBI Vaccines (“VBI”) for patients with chronic hepatitis B virus (HBV) infection.

                            Brand Name : VBI-2601

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 09, 2021

                            Lead Product(s) : BRII-179

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : VBI Vaccines

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth